Technical Analysis for SVRA - Savara, Inc.

Grade Last Price % Change Price Change
grade F 2.46 -0.81% -0.02
SVRA closed down 0.81 percent on Tuesday, July 23, 2019, on 40 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
4 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Down
See historical SVRA trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -0.81%
Inside Day Range Contraction -0.81%
Down 3 Days in a Row Weakness -0.81%
Down 4 Days in a Row Weakness -0.81%

Older signals for SVRA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:
Profile
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Medicine Medical Specialties Pharmaceutical Cystic Fibrosis Heart Failure Staphylococcus Aureus Heart Diseases Treatment Of Heart Failure Total Synthesis
Is SVRA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jul 15 Some Savara (NASDAQ:SVRA) Shareholders Have Taken A Painful 79% Share Price Drop
Jun 26 Hedge Funds Have Never Been More Bullish On Savara, Inc. (SVRA)
Jun 20 The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
Jun 19 Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
Jun 18 The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale
Jun 14 The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA
Jun 13 Savara to Present at the JMP Securities Life Sciences Conference
Jun 13 Mid-Afternoon Market Update: Dow Rises 80 Points; Red Robin Shares Spike Higher
Jun 13 Savara Plunges After Lung Disease Drug Fails Phase 3 Trial
Jun 13 Microcaps mostly among midday movers
See more SVRA news...
Indicators
Indicator Value
52 Week High 13.1
52 Week Low 2.32
Average Volume 745,248
200-Day Moving Average 7.9761
50-Day Moving Average 6.2714
20-Day Moving Average 2.5525
10-Day Moving Average 2.531
Average True Range 0.2635
ADX 51.23
+DI 12.7933
-DI 40.0564
Chandelier Exit (Long, 3 ATRs ) 1.9895
Chandelier Exit (Short, 3 ATRs ) 3.1205
Upper Bollinger Band 2.7659
Lower Bollinger Band 2.3391
Percent B (%b) 0.28
BandWidth 16.720862
MACD Line -0.8903
MACD Signal Line -1.1513
MACD Histogram 0.261
Fundamentals Value
Market Cap 59.54 Million
Num Shares 24.2 Million
EPS -3.50
Price-to-Earnings (P/E) Ratio -0.70
Price-to-Sales 526.42
Price-to-Book 2.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.55
Resistance 3 (R3) 2.55 2.52 2.54
Resistance 2 (R2) 2.52 2.50 2.52 2.53
Resistance 1 (R1) 2.49 2.48 2.48 2.49 2.52
Pivot Point 2.46 2.46 2.45 2.46 2.46
Support 1 (S1) 2.43 2.44 2.42 2.43 2.40
Support 2 (S2) 2.40 2.42 2.40 2.39
Support 3 (S3) 2.37 2.40 2.39
Support 4 (S4) 2.37